Oncotelic Therapeutics, Inc.
OTLC
$0.04
$0.001.27%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 250.35M | -1.05M | 277.90K | -298.70K | -600.90K |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 62.50K | 54.50K | 42.20K | 38.90K | 5.00K |
| Total Other Non-Cash Items | -250.92M | 508.80K | -551.60K | -6.20K | 367.70K |
| Change in Net Operating Assets | -275.10K | 177.10K | 105.40K | 99.00K | 124.30K |
| Cash from Operations | -783.00K | -307.00K | -126.20K | -167.00K | -103.90K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 462.90K | 628.00K | 135.00K | 160.00K | 41.00K |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 462.90K | 628.00K | 135.00K | 160.00K | 41.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -320.10K | 321.00K | 8.80K | -7.00K | -62.90K |